Coherus Claims Pegfilgrastim Payer Parity, But Parries Sales Queries
Executive Summary
Coherus BioSciences is hailing US payers’ responses to its January launch of its Udenyca pegfilgrastim biosimilar; but the US-based developer sidestepped investors’ questions around sales figures.